Mekinist 0.5mg 30s Tablets

$1,874.07

Tablets per box: 30, Manufacturer: Novartis

Description

Composition Trametinib 0.5 mg
Substitutes Trametinib 0.5 mg
Shipping class Cold chain shipment

Medicine Overview of Mekinist 0.5mg 30s Tablets

uses

Uses of Mekinist 0.5mg 30s Tablets

Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. Also Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
uses

Mekinist 0.5mg 30s Tablets side effects

Common

Rash, diarrhea, lymphedema. In combination with dabrafenib: also pyrexia, chills, fatigue, nausea, vomiting, hypertension, peripheral edema, headache, arthralgia, myalgia, dry skin, decreased appetite, hemorrhage, cough, dyspnea.
uses

How to use Mekinist 0.5mg 30s Tablets

Treatment with trametinib should only be initiated and supervised by a physician experienced in the administration of anti-cancer medicinal products. Before taking trametinib, patients must have confirmation of BRAF V600 mutation using a validated test.

How Mekinist 0.5mg 30s Tablets works

rametinib is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. MEK proteins are components of the extracellular signal-related kinase (ERK) pathway. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity.

In Depth Information on Mekinist 0.5mg 30s Tablets

Expert advice for Mekinist 0.5mg 30s Tablets

  • New malignancies, cutaneous and non-cutaneous, can occur when trametinib is used in combination with dabrafenib.
  • New primary melanoma was reported in patients receiving trametinib in combination with dabrafenib.
  • Based on its mechanism of action, dabrafenib may increase the risk of non-cutaneous malignancies when RAS mutations are present.
  • Haemorrhagic events, including major haemorrhagic events and fatal haemorrhages, occurred in patients taking trametinib as monotherapy and in combination with dabrafenib in the unresectable or metastatic melanoma.

Mekinist 0.5mg 30s Tablets related warnings

Special precautions for Mekinist 0.5mg 30s Tablets

alcohol
Alcohol
No specific data available. Please consult your doctor.
pregnancy
Pregnancy
WEIGH RISKS VS BENEFITS
There are no adequate and well-controlled studies of trametinib in pregnant women. Animal studies have shown reproductive toxicity. Trametinib should not be administered to pregnant women or nursing mothers. If trametinib is used during pregnancy, or if the patient becomes pregnant while taking trametinib, the patient should be informed of the potential hazard to the foetus.
lactation
Lactation
WEIGH RISKS VS BENEFITS
It is not known whether trametinib is excreted in human milk. Because many medicinal products are excreted in human milk, a risk to the breast-feeding infant cannot be excluded. A decision should be made whether to discontinue breast-feeding or discontinue trametinib, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
driving
Driving
caution
Trametinib has minor influence on the ability to drive or use machines. The clinical status of the patient and the adverse reaction profile should be borne in mind when considering the patient’s ability to perform tasks that require judgement, motor and cognitive skills. Patients should be made aware of potential for fatigue, dizziness or eye problems that might affect these activities.
kidney
Kidney
Renal failure has been identified in patients treated with trametinib in combination with dabrafenib in clinical trials.
liver
Liver
As metabolism and biliary excretion are the primary routes of elimination of trametinib, administration of trametinib should be undertaken with caution in patients with moderate to severe hepatic impairment

What if you miss a dose of Mekinist 0.5mg 30s Tablets?

If a dose of trametinib is missed, it should only be taken if it is more than 12 hours until the next scheduled dose.

Additional information

Weight 0.05 kg
Dimensions 6.2 × 4.6 × 8.4 cm